Merck (MRK)Officer sold ~$715K

~$715K

Approx. value · 8,500 sh @ $84.09

31K

Holds after · shares reported

Traded

Feb 19, 2025

Filed

Feb 20, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 15, 2025Congress · 1 personMembers of Congress: 3 sales
2. Jan 16, 2025Congress · 1 personMembers of Congress: 2 sales
3. Jan 17, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
4. Jan 24, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
5. Jan 27, 2025CongressDisclosed sale of MRK — reported range $15,001 - $50,000
6. Jan 28, 2025FDAFDA drug approval: Keytruda
7. Feb 5, 2025InsiderDirector purchased ~$1.33M of MRK shares in the open market
8. Feb 6, 2025Insider · 2 peopleInsiders: 1 purchase (~$250K), 1 sale (~$210K)
9. Feb 12, 2025Court · District Court, D. New JerseySecurities lawsuit filed: IN RE MERCK & CO., INC. SECURITIES LITIGATION
10. Feb 13, 2025InsiderOfficer sold ~$512K of MRK shares in the open market
11. Feb 19, 2025 · this disclosureInsiderOfficer sold ~$715K of MRK shares in the open market

What came next

1. Feb 24, 2025CongressDisclosed purchase of MRK — reported range $15,001 - $50,000
2. Feb 25, 2025CongressDisclosed sale of MRK — reported range $15,001 - $50,000
3. Feb 26, 2025CongressDisclosed purchase of MRK — reported range $15,001 - $50,000
4. Mar 3, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
5. Mar 19, 2025FDAFDA drug approval: Keytruda
6. Mar 20, 2025CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
7. Mar 31, 2025CongressDisclosed partial sale of MRK — reported range $15,001 - $50,000
8. Apr 8, 2025CongressDisclosed purchase of MRK — reported range $15,001 - $50,000
9. Apr 9, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
10. Apr 15, 2025FDAFDA drug approval: Welireg
11. Apr 15, 2025FDAFDA drug approval: Welireg
12. Apr 17, 2025CongressDisclosed sale of MRK — reported range $15,001 - $50,000
13. Apr 21, 2025FDAFDA drug approval: Keytruda
14. Apr 21, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
15. Apr 25, 2025InsiderOfficer sold ~$353K of MRK shares in the open market
16. Apr 29, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
17. May 5, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
18. May 14, 2025FDAFDA drug approval: Welireg
19. May 15, 2025CongressDisclosed sale of MRK — reported range $15,001 - $50,000
20. May 22, 2025FDAFDA drug approval: Keytruda

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Merck

For Merck, OQRO holds 26 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 123 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRK page.

Other recent filings by Johannes Jacobus Oosthuizen, President, U.S. Market

• SEC Form 4 at Merck (MRK)Feb 6, 2026

The full history of Johannes Jacobus Oosthuizen, President, U.S. Market is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Merck

• House Clerk periodic transaction reportOct 7, 2026
• USAspending.gov award recordSep 17, 2026
• House Clerk periodic transaction reportSep 9, 2026
• House Clerk periodic transaction reportSep 9, 2026
• SEC Form 13F-HRAug 26, 2026
• SEC Form 13F-HRAug 25, 2026

Everything OQRO holds on this company is on its MRK page.